Best Life Sciences Companies in Sydney, Australia
The 134 best Life Sciences companies in Sydney, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novotech.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Sydney
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Novotech 🦄 Provider of clinical research services across all trial phases and therapeutic areas 72Funding top 25%Fin. health top 26%Product top 26%Innovation top 34% All 10 signals ▾Fundingtop 25% Fin. healthtop 26% Producttop 26% Innovationtop 34% Markettop 36% Techtop 37% Moattop 37% Growthbottom 46% Globalbottom 39% Newsbottom 34% Funding: Raised $255M across 2 rounds · 2 rounds over 13 yrs (0.2/yr) Fin. health: Revenue ~$336M · Revenue +4% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $255M | 14 mo ago | 51 | — | DrupalApple iCloud MailMicrosoft 365+28 | Top 5M | — | 1 partnership |
| 2 | Kazia Therapeutics Developer of small molecules for the treatment of cancer | $86M | 6 mo ago | 9 | — | ZURB FoundationMicrosoft ASP.NETAmazon Web Services+14 | Top 10M | 3 patents Novel functionalized benzopyran compounds for therapeutic drug development | 1 expansion · 1 award |
| 3 | Viralytics Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer. | $83M | 101 mo ago | 6 | — | — | — | 59 patents Oncolytic virus-based cancer therapies and combination immuno‑stimulatory treatments | — |
| 4 | SpeeDx Provider of qPCR-based molecular diagnostics platform | $78M | 39 mo ago | 113 | Alison Todd Co-Founder | WordPressMySQLPHP+41 | Top 5M | — | 5 partnerships |
| 5 | Benitec Biopharma Limited Developer of RNAi-based therapies for infectious, ocular, and genetic diseases | $71M | 25 mo ago | 18 | — | BootstrapApache HTTP ServerjQuery+10 | Top 10M | 120 patents Engineered AAV gene‑therapy vectors and OPMD therapeutic reagents for muscle disease treatment | — |
| 6 | Pharmaxis Developer of drugs for inflammatory and fibrotic diseases | $68M | 46 mo ago | 93 | Gary Phillips CEO | — | — | 145 patents Small-molecule lysyl oxidase and amine oxidase inhibitors for therapeutic use | — |
| 7 | Immutep Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $66M | 60 mo ago | 35 | Marc Voigt CEO | WordPressMySQLPHP+12 | Top 5M | — | — |
| 8 | Heart Ware Implantable ventricular assist devices | $55M | 202 mo ago | — | Doug Godshall President & CEO | — | — | — | — |
| 9 | Inventia Life Science Developer of 3D bio-printers | $50M | 48 mo ago | 90 | Aidan O'Mahony Co-Founder & CTO | HubSpot CMS HubApple iCloud MailMicrosoft 365+19 | Top 10M | 43 patents 3D bioprinting hardware and processes for fabricating tissue constructs | — |
| 10 | Clinical Genomics Biomarker-based blood tests for early cancer detection | $41M | 96 mo ago | 50 | Susanne Pedersen Co-Founder & CSO | — | — | 256 patents Colorectal cancer epigenetic methylation biomarker panels for diagnostic testing | — |
| 11 | Recce Developer of antibiotics for drug-resistant bacteria and cancer treatments | $41M | 12 mo ago | — | James Graham CEO | WordPressMySQLPHP+26 | Top 50M | 8 patents Antimicrobial polymer therapeutics for viral and bacterial infection treatment | 4 partnerships |
| 12 | Actinogen Mdical Developer of therapeutics for the treatment of cognitive impairment | $40M | 54 mo ago | — | Steven Gourlay CEO & Managing Director | WordPressMySQLPHP+18 | Top 10M | — | 1 award |
| 13 | Clarity Pharmaceuticals Developer of drugs to treat cancer | $28M | 10 mo ago | 41 | — | WordPress Block EditorwpBakeryWordPress+24 | Top 5M | 129 patents Targeted radiopharmaceuticals for prostate and neuroendocrine cancer imaging and therapy | — |
| 14 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 12 mo ago | 2 | Daniel Kenny Chief Executive Officer | WordPressMySQLPHP+28 | Top 10M | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 15 | Star Combo Dietary supplements for improving strength and focus | $25M | 70 mo ago | — | Su Zhang CEO | PHPThinkPHPBootstrap+5 | Top 10M | — | — |
| 16 | Topelia Developer of antiviral triple therapy for coronavirus infection | $25M | 56 mo ago | — | David Fox CEO | — | — | — | — |
| 17 | Medlab Developer of pharmaceuticals, nutraceuticals and biologics for treating chronic diseases | $23M | 53 mo ago | 48 | — | — | — | — | — |
| 18 | Simavita Provider of urinary incontinence assessment tool | $19M | 65 mo ago | 48 | — | — | — | — | — |
| 19 | Infensa Developer of peptide drugs for cardiovascular disorders | $16M | 47 mo ago | 1 | Mark Smythe Chief Executive Officer | — | — | — | — |
| 20 | Elastagen Company offering solutions for cell growth and tissue repair through their Elastin technology | $15M | 116 mo ago | 5 | — | — | — | — | — |
| 21 | Psylo Developer of psychedelic derived therapeutic for mental illness | $14M | 24 mo ago | 24 | Josh Ismin Co-Founder & CEO | — | — | — | — |
| 22 | The Beauty Chef Developer of probiotics for improving gut health | $10M | 79 mo ago | 25 | Carla Oates Founder & CEO | Cart FunctionalityShopifyBootstrap+47 | Top 5M | — | — |
| 23 | Minomic Non-invasive blood tests for cancer | $8M | 114 mo ago | 14 | Brad Walsh Founder & CEO | — | — | — | — |
| 24 | Haemalogix Developer of immunotherapies for blood cancers and autoimmune diseases | $7M | 57 mo ago | 8 | — | — | — | 23 patents Therapeutic peptides and antibody-based drugs targeting myeloma antigens. | — |
| 25 | TruScreen Cervical cancer screening device | $4M | 110 mo ago | — | — | Cart FunctionalitySquarespace CommerceSquarespace+16 | Top 50M | — | 1 partnership · 1 expansion |
| 26 | Pharmamark Provider of microencapsulation technology for nutraceuticals and bio-active compounds | $4M | 82 mo ago | — | Guy Drummond Co-Founder & CEO | — | — | — | — |
| 27 | Evrima Evrima Technologies expedites the clinical trial process by enabling the discovery and registration of active… | $3M | 45 mo ago | 24 | Charlotte Bradshaw Founder & CEO | HubSpot CMS HubEnvoycore-js+17 | Top 10M | — | — |
| 28 | Beroni Group Developer of cell therapies for treating cancer | $2M | 32 mo ago | 65 | Jacky Zhang CEO | — | — | — | — |
| 29 | Celosia Therapeutics Developer of therapeutics for neurodegenerative diseases | $2M | 42 mo ago | 1 | Lars Ittner Co-Founder | WordPress Block EditorWordPressMySQL+13 | Top 10M | 9 patents Protein therapeutics targeting phosphorylated tau and p38γ for neurodegenerative disease treatment | — |
| 30 | The Best of Moi Internet-first brand offering wellness and nutritional supplements | $850K | 35 mo ago | 3 | Lu Nan Founder & CEO | — | — | — | — |
| 31 | Andi Provider of wearable device and app for monitoring body vitals parameters | $600K | 51 mo ago | 4 | — | — | — | — | — |
| 32 | Neoclinical Enabling patient recruitment through a searchable registry of clinical trials | $466K | 132 mo ago | 11 | Geoff Denman Co-Founder & CEO | — | — | — | — |
| 33 | Respiratory Innovations Medical procedures for monitoring breathing functions and guidance | $400K | 116 mo ago | — | Sean Pollock COO & Co-Founder | — | — | — | — |
Top 12 Life Sciences companies in Sydney
#1
Public · Sydney, New South Wales · founded 1994 · 9 employees$85.7Mraised▾
Developer of small molecules for the treatment of cancer. The lead product Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway which regulates growth and cell division is used for the treatment of glioblastoma, DIPG, CNS lymphoma, and brain metastases. Another drug VT801 is a small molecule inhibitor of VEGFR3, which helps in the development of new blood vessels and lymphatic vessels in a growing tumour.
- Dec 2025Post IPO$55.3M
- Aug 2025Post IPO$2.1M
- Jan 2023Post IPO$3.1M
- Oct 2020Post IPO$11.8M
#2
Novotech 🦄Acquired · Sydney, New South Wales · founded 2002 · 51 employees$255Mraised▾
Provider of clinical research services across all trial phases and therapeutic areas. It offers services including medical and regulatory consulting, patient recruitment, site selection, early phase trials, clinical operations, project management, site management, biometrics, data management, virtual clinical trials, real-world data analysis, and laboratory services. It also provides specialized services for oncology, pharmacometrics, drug development consulting, GMO solutions, liver disease, infectious diseases, vaccines, and orphan/rare diseases. It focuses on clinical and regulatory strategy to assist biotechnology companies in conducting early-phase clinical trials.
- Mar 2025Seed—
- Jan 2022Conventional Debt$505M
- Jan 2022PE$255M
- Feb 2021PE—
#3
Public · Sydney, New South Wales · founded 2010 · 41 employees$28.1Mraised▾
Developer of drugs to treat cancer. The company utilizes radiopharmaceutical technology for developing targeted therapies. The company has developed drug candidates used for the neuroendocrine tumour, neuroblastoma, colorectal, glioma, and prostate diseases. The company has also developed programs for companion diagnostics in the preclinical stage.
- Jul 2025Post IPO$133.3M
- Mar 2024Post IPO$79M
- Dec 2020Series B$25M
- Jun 2016Grant (prize money)$2.5M
#4
Public · Sydney, New South Wales · founded 2007$40.8Mraised▾
Developer of antibiotics for drug-resistant bacteria and cancer treatments. The company's pipeline includes RECCE 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE 435 (R435) as an orally administered therapy for bacterial infections; and RECCE 529 (R529) for viral infections.
- Jun 2025Post IPO$4.8M
- Apr 2025Post IPO$10.1M
- Sep 2020Post IPO$20.1M
- Oct 2019Post IPO$4.6M
#5
Public · Sydney, New South Wales · founded 2005 · 2 employees$27.8Mraised▾
Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.
- May 2025Post IPO$8.7M
- Apr 2022Post IPO$10M
- Feb 2016Post IPO$7.1M
- 2005Post IPO$2M
#6
Public · Sydney, New South Wales · founded 1997 · 18 employees$70.5Mraised▾
Developer of RNAi-based therapies for infectious, ocular, and genetic diseases. The company specializes in genetic medicines that combine gene therapy with DNA-directed RNA interference (ddRNAi) for sustained gene silencing. The company targets chronic and life-threatening conditions like Oculopharyngeal Muscular Dystrophy (OPMD), where its lead candidate BB-301 aims to address moderate dysphagia through a single administration.
- Apr 2024Post IPO$40M
- Sep 2019Post IPO$2.2M
- Feb 2014Post IPO$28.3M
#7
Series C · Sydney, New South Wales · founded 2009 · 113 employees$78Mraised▾
Provider of qPCR-based molecular diagnostics platform. The company's products include multiplexed assays for HSV-1 and -2, VZV, and Syphilis, and detecting the presence of Mycoplasma genitalium as well as antibiotic resistance. The products are based on plexZyme technology where primers amplify target nucleic acid sequences and produce an amplicon.
- Feb 2023Series C$26M
- May 2021Grant (prize money)—
- Sep 2020Grant (prize money)—
- Feb 2020Series B$15M
#8
Seed · Sydney, New South Wales · founded 2021 · 24 employees$14.2Mraised▾
Developer of psychedelic derived therapeutic for mental illness. It provides psychedelics drugs that are improved treatments against selective serotonin reuptake inhibitors (SSRI) medications, allowing patients to recover from severe mental illness like treatment-resistant depression, anxiety, addiction, and others.
- Jun 2024Seed$8M
- Oct 2022Seed$5M
- Oct 2021Seed$1.2M
#9
Public · Sydney, New South Wales · founded 1998 · 93 employees$68.2Mraised▾
Developer of drugs for inflammatory and fibrotic diseases. The product pipeline has mechanism-based inhibitors of amine oxidases which include Pan-LOX and PXS-5505 for Myelofibrosis, Liver, and pancreatic cancer. It also offers LOXL-2 and PXS-5382 for antifibrotic CKD / IPF / NASH, Pan-LOXand PXS-6302 for anti-scarring, PXS-4699 for anti-inflammatory muscular dystrophy, and PXS-5370 for anti-inflammatory multiple indications.
- Aug 2022Post IPO$5M
- Apr 2021Post IPO$3.4M
- Sep 2020Grant (prize money)$733.8K
- Aug 2018Post IPO$17.7M
#10
Acquired · Sydney, New South Wales · founded 2001 · 35 employees$65.8Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's product line include Eftilagimod alpha for metastatic cancers, IMP761, a humanized IgG4 monoclonal antibody for immunological diseases, and LAG525 for autoimmune diseases.
- Jun 2021Post IPO$44.9M
- Aug 2020Grant (prize money)—
- Sep 2019Post IPO$5M
- Jul 2019Post IPO$520.7K
#11
Series B · Sydney, New South Wales · founded 2013 · 90 employees$50Mraised▾
Operator of a bioprinting platform intended to help accelerate cancer research, drug discovery, and develop regenerative medicine. The company's digital 3D bioprinting technology allows rapid fabrication of living biological structures to accelerate the discovery of drugs for cancer and other diseases, enabling biomedical companies with an efficient bioprinting tool of 3D cell-based assays for research.
#12
Public · Sydney, New South Wales · founded 1999$40.4Mraised▾
Developer of therapeutics for the treatment of cognitive impairment. The company is focused on developing a treatment for cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. Its lead product Xanamem is a novel drug for Alzheimer’s disease, which has been specifically designed to block the production of cortisol in the brain.
- Nov 2021Post IPO—
- May 2018Post IPO$7.1M
- Dec 2017Post IPO$5.3M
- Apr 2015Post IPO$8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Sydney is moving
A read on the academic research around Biotechnology in Sydney — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 80 papers.
Sydney's University of Sydney, UNSW, and Western Sydney University optimistically research aquaculture disease, antibiotic environmental impacts, and plant-microbe immunity, with recent output surging post-2020.
- The University of Sydney28
- UNSW Sydney26
- Western Sydney University14
- University of Technology Sydney10
- University of Sydney3
- Biosensor3
- Mutant3
- Aquaculture2
- In vivo2
- Bottleneck2
- Antimicrobial4
- Antibiotic resistance3
- Bacteria3
- Immune system3
- Metagenomics2
- Agriculture3
- Sustainable agriculture2
- Antibiotic resistance2
- Antibiotics2
- Gene2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.